TL1A antibodies are a new class of drugs designed to block a specific immune signaling molecule called TL1A, and they have generated substantial excitement in gastroenterology because early clinical trials show they can reduce inflammation in inflammatory bowel disease while also appearing to reverse intestinal scarring, something no approved IBD therapy reliably does. Three anti-TL1A monoclonal antibodies have already advanced into large phase 3 trials: tulisokibart, afimkibart, and duvakitug. The clinical data so far suggest these drugs could reshape how Crohn’s disease and ulcerative colitis are treated, and research is probing whether TL1A blockade could help in rheumatoid arthritis and other inflammatory conditions as well.
What TL1A Does and Why It Matters
TL1A (short for TNF-like ligand 1A, also known by its gene name TNFSF15) is a protein that belongs to the same family as tumor necrosis factor, one of the most important immune signaling molecules in the body. TL1A was first identified as a ligand that specifically binds to a receptor called DR3 on the surface of immune cells, triggering a cascade of pro-inflammatory signals inside the cell. When TL1A latches onto DR3, it activates a key inflammatory switch called NF-κB, which ramps up the production of other inflammatory molecules and drives immune cells to multiply and attack.1Immunity. TL1A, a Novel TNF-like Ligand That Interacts with DR3 and TR6 and Promotes T Cell Activation The body does have a natural brake on TL1A: a decoy receptor called DcR3 that soaks up TL1A before it can reach DR3. DcR3 also neutralizes two other inflammatory signals, FasL and LIGHT, making it a broad-spectrum dampener of immune activation.2PubMed Central. Decoy strategies: the structure of TL1A:DcR3 complex
TL1A does not just talk to one type of immune cell. When immune cells called antigen-presenting cells release TL1A, it co-stimulates a wide variety of lymphocytes, boosting proliferation and cytokine production across multiple subsets of T cells (Th1, Th2, Th17, Th9, and regulatory T cells) as well as all types of innate lymphoid cells.3PubMed Central. TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity That breadth of influence is part of what makes TL1A an attractive drug target: blocking it could quiet down multiple arms of the immune response simultaneously, rather than just one.
TL1A in Inflammatory Bowel Disease
The connection between TL1A and IBD is not just theoretical. Studies of intestinal tissue from patients with Crohn’s disease and ulcerative colitis found that TL1A levels are elevated in inflamed gut, with the strongest increases in areas actively affected by Crohn’s disease. The protein was found to be produced by macrophages and T cells in Crohn’s patients, and by plasma cells in ulcerative colitis patients, all congregating in the lamina propria, the tissue layer just beneath the gut lining where much of the immune battle in IBD takes place.4PubMed. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease
There is also an interesting layer involving gut bacteria. Researchers found that certain IBD-associated microbes trigger immune cells in the gut (specifically a type called CX3CR1-positive mononuclear phagocytes) to release TL1A. In acute colitis, some TL1A signaling is actually protective: it drives a subset of innate lymphoid cells to produce a healing molecule called IL-22 that supports the gut barrier. But in chronic disease, TL1A tips the balance toward harm by promoting activation of pathogenic T cells through a co-stimulatory molecule called OX40L.5PubMed Central. Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis This dual role is a nuance worth watching: in an ongoing flare, TL1A may help the gut try to heal, but in established, chronic inflammation, TL1A becomes a driver of the damage.
The Fibrosis Angle
Here is where TL1A antibodies stand apart from existing IBD medications. Current biologics, such as anti-TNF drugs and anti-interleukin therapies, are effective at dialing down inflammation, but they have not convincingly been shown to reverse intestinal fibrosis. Fibrosis, the buildup of scar tissue in the gut wall, is a major contributor to complications in Crohn’s disease like bowel strictures and obstructions. It develops partly because inflammatory signals push fibroblasts and myofibroblasts to produce excess collagen.
TL1A directly drives this fibrotic process. In laboratory studies, TL1A promoted activation of colonic fibroblasts and increased their production of collagen and other extracellular matrix components through a well-known scarring pathway (the TGF-β1/Smad3 signaling route).6PubMed. TL1A Promotes Fibrogenesis in Colonic Fibroblasts via the TGF-β1/Smad3 Signaling Pathway Crucially, animal studies found that neutralizing TL1A with an antibody did not merely slow further scarring but actually reversed established colonic fibrosis, bringing collagen levels back to what they were before inflammation began. Blocking TL1A also reduced the number of fibroblasts and myofibroblasts in the tissue.7PubMed Central. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis Those results, while still from animal models, are a significant reason TL1A antibodies have attracted so much investment. If the same reversal holds in humans, it could change the trajectory of Crohn’s disease for many patients who currently face surgery for stricturing disease.
Early evidence from human trials is tentatively encouraging. Mucosal tissue analyses from phase 2 trials have shown that anti-TL1A treatment suppresses genes related to extracellular matrix production and fibrotic pathways in the gut, providing the first human-tissue confirmation that the anti-fibrotic effects seen in animals may translate clinically. Formal demonstration will require long-term data from the ongoing phase 3 programs.
Clinical Trial Results So Far
Three anti-TL1A antibodies have progressed furthest in clinical development, each produced by a different pharmaceutical company. The trial data to date come from phase 2 studies, which are designed primarily to establish whether a drug works well enough to justify larger trials, and to figure out dosing.
Tulisokibart in Ulcerative Colitis
Tulisokibart (previously known as PRA023) is the furthest along. In a phase 2 trial of 135 patients with moderately to severely active ulcerative colitis, roughly a quarter of patients receiving tulisokibart achieved clinical remission at 12 weeks, compared to about 1% on placebo. Secondary measures, including symptom relief, mucosal healing, and quality-of-life scores, also favored the drug.8New England Journal of Medicine. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis That gap between active drug and placebo is large enough that it attracted major attention when the results were presented.
Tulisokibart has also been tested in Crohn’s disease. In a phase 2a induction trial of 55 patients, most side effects were mild to moderate. The most common adverse events were common infections (COVID-19, urinary tract infections), nasopharyngitis, fatigue, and flares of the underlying Crohn’s disease. About 15% of participants had a serious adverse event, but none were judged by investigators to be related to the study drug, and there were no deaths.9PubMed. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn’s disease: a phase 2a induction trial
Afimkibart in Ulcerative Colitis
Afimkibart was studied in the TUSCANY-2 trial, a phase 2b study that tested three different doses (50 mg, 150 mg, and 450 mg) against placebo in patients with moderately to severely active ulcerative colitis. Using the trial’s primary scoring system, clinical remission rates ranged from about 23% to 26% across the dose groups, compared with 12% on placebo. Those differences did not reach conventional statistical significance. However, using an updated scoring method in line with newer FDA guidance (the modified Mayo score), remission rates climbed to 30–35% on afimkibart versus 12% on placebo, and these differences were clinically meaningful. Rates of side effects during the induction period were similar between afimkibart and placebo.10PubMed. Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2)
Duvakitug in Both Crohn’s and Ulcerative Colitis
Duvakitug (previously TEV-48574) has been tested in a phase 2b “basket” trial covering both Crohn’s disease and ulcerative colitis, and results presented at gastroenterology conferences have reported efficacy with a favorable safety profile. In its first-in-human study in healthy volunteers and asthma patients, duvakitug showed slow absorption with peak blood concentrations appearing about three to four days after dosing, dose-proportional exposure, and a half-life of roughly a week.11Journal of Crohn’s and Colitis. First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients All three antibodies have now moved into phase 3 trials.
How Anti-TL1A Antibodies Physically Block the Signal
Understanding how these antibodies work at the molecular level matters because it explains why they are effective. Structural studies using hydrogen-deuterium exchange mass spectrometry revealed that at least one anti-TL1A antibody binds to a discontinuous epitope on TL1A, meaning it grabs onto several separate patches of the protein’s surface that are close together in three-dimensional space but far apart in the protein’s linear sequence. These patches happen to sit right within the area where TL1A normally contacts DR3, so the antibody physically blocks the receptor from docking.12PubMed Central. Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A Interaction The result is that TL1A cannot deliver its inflammatory signal even though it is still floating around in the tissue. This is a competitive blocking strategy: the antibody does not destroy TL1A or remove it from circulation, it just occupies the spot where DR3 would bind.
A separate pharmacokinetic study of the early anti-TL1A antibody PF-06480605 found that the drug behaved like a typical IgG monoclonal antibody, with a long terminal half-life of about 20 days, slow clearance, and an additional component of target-mediated clearance, meaning that some of the drug is consumed by binding to its TL1A target rather than just being metabolized normally.13PAGE. Population Pharmacokinetics and Pharmacodynamics of PF-06480605, an Anti-TL1A Monoclonal Antibody, in Healthy Subjects and Patients with Ulcerative Colitis That long half-life is part of why these drugs can be dosed relatively infrequently, a practical advantage for patients tired of frequent injections or infusions.
Biomarker-Guided Treatment
One of the more intriguing aspects of TL1A antibody development is the push toward using biomarkers to identify which patients are most likely to respond. Not everyone with IBD has the same degree of TL1A-driven disease, and early data suggest that patients with higher expression of the TNFSF15 gene or certain genetic variants in that gene tend to respond better to anti-TL1A treatment. The tulisokibart ulcerative colitis trial used a diagnostic test to identify patients considered most likely to respond. Among those who tested positive, clinical remission rates were higher than in the overall trial population, with about a third of test-positive patients on the drug achieving remission versus roughly 11% on placebo.14New England Journal of Medicine. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
Analysis of gut tissue samples from trial participants has added granularity. In tulisokibart responders, tissue gene expression showed suppression of IL-17-related pathways, while the TUSCANY-2 trial of afimkibart also found numerically better outcomes in biomarker-positive patients.15Journal of Crohn’s and Colitis. TL1A as a therapeutic renaissance in inflammatory bowel disease: a systematic review from molecular mechanisms to clinical translation The long-term vision is a companion diagnostic that combines genetic polymorphisms, tissue gene-expression profiles, and blood-based biomarkers to select patients upfront. If such a test can be validated, it would make anti-TL1A therapy one of the first examples of genuine precision medicine in IBD, where treatment is chosen based on a patient’s individual biology rather than trial and error.
Safety So Far
Across the phase 2 programs, the safety profile of anti-TL1A antibodies has been largely reassuring. In the tulisokibart Crohn’s disease trial, about three-quarters of participants experienced at least one adverse event, but most were mild to moderate: common infections, fatigue, and worsening of the underlying disease were the most frequent. No serious adverse events were attributed to the drug.16PubMed. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn’s disease: a phase 2a induction trial In the TUSCANY-2 trial of afimkibart, roughly half of patients in the induction phase reported at least one treatment-emergent adverse event, and rates were similar between the drug and placebo groups.17PubMed. Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2)
That said, phase 2 trials are not large enough or long enough to detect rare side effects. TL1A plays roles beyond the gut, and its blockade could theoretically have unintended consequences in other tissues or during infections. Phase 3 trials will enroll thousands of patients and run for longer, providing a much clearer picture. It is worth remembering that earlier biologic classes for IBD, including anti-TNF drugs, also looked clean in early trials and later revealed uncommon risks (certain infections, rare malignancies) that only became apparent with wide use.
Potential Beyond the Gut
TL1A is not exclusively a gut cytokine. DR3 is expressed on immune cells throughout the body, and elevated TL1A levels have been documented in other inflammatory and autoimmune conditions. In rheumatoid arthritis, circulating TL1A levels rise early in the disease course and appear to depend partly on TNF itself. In animal models of arthritis, blocking TL1A reduced joint inflammation and bone erosion.18PubMed Central. Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF Clinical trials in rheumatoid arthritis have not yet reported results, but the preclinical rationale is strong enough that the pathway is being investigated.
Allergic lung inflammation is another area of interest. TL1A can activate type 2 innate lymphoid cells in the airways, the same cells that drive asthma and allergic responses. The first-in-human study of duvakitug included asthma patients alongside healthy volunteers, suggesting that the developers see potential beyond IBD.19Journal of Crohn’s and Colitis. First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients If the pathway proves to be involved in fibrosis outside the gut, such as pulmonary or hepatic fibrosis, the therapeutic implications could expand considerably.
Next-Generation Designs
The current wave of anti-TL1A antibodies are all straightforward monoclonal antibodies that block TL1A alone. But researchers are already engineering more complex molecules. One group has developed a bispecific antibody that simultaneously blocks TL1A and activates PD-1, an immune checkpoint receptor. The idea is to dampen pathogenic immune activation through two complementary mechanisms at once and also selectively deplete the most activated T cells through antibody-dependent cellular cytotoxicity.20The Journal of Immunology. A Novel Dual-targeting PD-1 and TL1A Bispecific Antibody with Synergistic Effect for Immune Disorders Treatment
Another bispecific antibody, called LBL-053, targets TL1A and the p40 subunit shared by IL-12 and IL-23, two cytokines already validated as IBD drug targets (ustekinumab blocks p40). In laboratory assays, LBL-053 blocked TL1A from binding DR3, left the TL1A–DcR3 decoy interaction intact, and simultaneously blocked IL-23 signaling. When both pathways were inhibited together, the suppression of inflammatory cytokine production by T cells was greater than what either arm achieved alone or what a combination of two separate antibodies could achieve.21Arthritis & Rheumatology. LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders The preservation of the DcR3 decoy interaction is a thoughtful design choice: it means the drug blocks the harmful TL1A signal through DR3 while leaving the body’s own natural brake on TL1A partially intact.
These next-generation molecules are still in preclinical or very early clinical stages, but they illustrate a broader trend in IBD drug development: moving from single-target biologics toward drugs that hit two or more pathways simultaneously. If the safety profiles hold up, combination-mechanism drugs could improve response rates, reduce the need for stacking separate medications, and offer options for patients who stop responding to single-target therapies.
How Anti-TL1A Fits Into the Existing IBD Treatment Landscape
For patients and clinicians trying to place these drugs in context, anti-TL1A antibodies fill a niche that current therapies leave open. Anti-TNF drugs (like infliximab and adalimumab) remain the most widely used biologics in IBD, but a sizable fraction of patients either do not respond initially or lose response over time. Anti-integrin therapies (vedolizumab), anti-IL-12/23 agents (ustekinumab), and selective IL-23 blockers (risankizumab, guselkumab) offer alternatives, but none have demonstrated anti-fibrotic effects. The combination of inflammation control and potential fibrosis reversal is what makes TL1A blockade genuinely new rather than just another option in a crowded space.
Whether anti-TL1A antibodies will be used as first-line biologics, as second- or third-line treatments after anti-TNF failure, or preferentially in patients with stricturing Crohn’s disease will depend on the phase 3 data. The biomarker angle could also shape prescribing: if companion diagnostics reliably identify high-responders, anti-TL1A therapy might be reserved for biomarker-positive patients while others are directed to different mechanisms. That kind of stratification would be a departure from the current “try it and see” approach that dominates IBD care. The field is watching the phase 3 readouts closely, with results expected over the next couple of years.